Among male patients (hazard ratio [ HR ] = 1.666, P = 0.004), larger tumor diameter ( HR = 2.643, P < 0.001), high tumor stage
( HR = 1.874, P < 0.001), high tumor grade ( HR = 1.645, P = 0.004), lymph node metastasis ( HR = 2.910, P < 0.001), and high pretreatment NLR ( HR = 2.240, P < 0.001) were significantly associated with poor CSS in univariate analysis [Figure 2].
Stages of tumor: Tumor stage
2 was found to be higher 23 (39.7%) followed by tumor stage
3 in 17 (29.3%), stage 4 in 11 (19%) while stage 1 tumor was found in 7 (12.1%) patients.
Clinicopathological parameters in our study involved patients' age, gender, tumor size, lymph node metastasis, tumor grade, and tumor stage
. miR-204 level was significantly associated with no lymph node metastasis (P = 0.003) and early tumor stages
(stages I-II; P = 0.048).
Clinical data (gender, age, tumor location, and tumor stage
) were obtained from medical records.
In our previous report, we identified a -31C/G polymorphism located within the CDE/CHR repressor binding site, which was found to be associated with tumor stage
and grade in UCs .
(1,2) Before the implementation of targeted therapies, LN metastases were considered to be a portent of markedly decreased survival, regardless of the tumor stage
. (3,4) However, the role of lymphadenectomy and the relative benefit of retroperitoneal LN dissection in the context of modern adjunctive therapies have not been conclusively addressed in the clinical literature, and there are only limited studies available in the pathologic literature.
The most important determinant of survival in ovarian carcinoma cases is tumor stage
. Most patients presenting with disease confined to the ovaries (stage 1) can be cured, with a 5-year survival rate of >90% (1).
The BRCA1 and BRCA2 mutation carriers in this study did not differ in regard to tumor stage
, grade, or histology.
In addition, the analysis of the PTEN gene and the loss of PTEN function was predictive of patient survival outcome at a statistically significant level after adjusting for tumor stage
(p-value = 0.009), suggesting that PTEN status provides additional prognostic information not otherwise available to physicians.
Other factors that appeared to be associated with a poor prognosis were (1) older age, (2) a primary tumor location in a paranasal sinus, (3) an advanced tumor stage
, (4) an external approach to surgery, and (5) the absence of adjuvant radiotherapy.
Although ROMA was significantly more sensitive in other comparisons based on tumor stage